Salix Pharmaceuticals Ltd. (SLXP)
-NasdaqGS 59.28 
0.09(0.15%) May 17, 4:00PM EDT|After Hours
:
59.21 0.07 (0.11%) May 17, 4:10PM EDT
| Prev Close: | 59.19 |
|---|
| Open: | 59.27 |
|---|
| Bid: | N/A |
|---|
| Ask: | 62.59 x 200 |
|---|
| 1y Target Est: | 58.93 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 58.75 - 59.56 |
|---|
| 52wk Range: | 37.52 - 60.20 |
|---|
| Volume: | 420,834 |
|---|
| Avg Vol (3m): | 528,054 |
|---|
| Market Cap: | 3.63B |
|---|
| P/E (ttm): | 48.75 |
|---|
| EPS (ttm): | 1.22 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- SALIX PHARMACEUTICALS LTD FinancialsEDGAR Online Financials(Fri, May 17)
- Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013Business Wire(Fri, May 17)
- Good News for Roche's TarcevaZacks(Thu, May 16)
- Good News for Novartis' IlarisZacks(Wed, May 15)
- FDA Accepts Merck BLAZacks(Wed, May 15)
- Salix Stock Hits New 52-Week High (SLXP)at TheStreet(Wed, May 15)
- Salix Beats on EarningsZacks(Tue, May 14)
- Investors are Digesting These Healthcare Stock Earnings Insightsat Wall St. Cheat Sheet(Sun, May 12)
- Salix Pharmaceuticals Ltd. Earnings Call Insights: Fulyzaq and Aprisoat Wall St. Cheat Sheet(Sat, May 11)
- The Gory Details on Salix Pharmaceuticals's Double Missat Motley Fool(Fri, May 10)
- Priceline Is a Buy and 4 More Analyst Opinions To Know Nowat Wall St. Cheat Sheet(Fri, May 10)
- SALIX PHARMACEUTICALS LTD Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Salix Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Salix Pharmaceuticals Earnings: Here’s Why Investors are Excited Nowat Wall St. Cheat Sheet(Thu, May 9)
- Salix Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET todayCCBN(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | 13.20 |
|---|
| P/S (ttm): | 4.73 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.39 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.80 |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 0.85 |
|---|
Business Summary
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States.
View More